Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Materials and methods br Results br
2024-09-04

Materials and methods Results Discussion Many studies investigate the role of 12/15-LOX in cancer cell,23, 24, 25 however we here first found that host 12/15-LOX also plays an important role in metastasis progression. We have demonstrated that 12(S)-HETE increased melanoma cell adhesion to
-
Another possible explanation of the increased
2024-09-04

Another possible explanation of the increased BOP levels might be excess cement. In the present study, cement-retained fixed restorations were used. Cementation of the implant-supported restorations may cause the insufficient removal of excess cement from the peri-implant sulcus. Also, the placement
-
Most clinically approved antiangiogenic drugs
2024-09-04

Most clinically approved antiangiogenic drugs are aimed at blocking the action of vascular endothelial growth factor, or VEGF, which is accepted to be the most important tumor-derived angiogenic factor, stimulating proliferation and migration of endothelial cells, as well as branching of vessels (Fe
-
A phase I trial has recently evaluated
2024-09-04

A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with
-
A requirement for active PKA signaling during LTD induction
2024-09-04

A requirement for active PKA signaling during LTD induction was proposed in studies characterizing AKAP150 D36mice (Lu et al., 2008), but linking impaired LTD in D36 mice to PKA signaling deficits was complicated by subsequent work showing substantial increases in the number of dendritic spines and
-
Elevated aminopeptidase activities were often detected in or
2024-09-03

Elevated aminopeptidase activities were often detected in organs of plant with accelerated protein turnover, such as leaves and petals during senescence, fruits maturation or in germinating seeds [22]. Moreover, it was proven that these enzymes take part in defense responses [[23], [24], [25]]. Part
-
br Regulation of BCAA catabolism The BCAA catabolic system i
2024-09-03

Regulation of BCAA catabolism The BCAA catabolic system is equipped in mammalian cells to dispose of excess BCAAs, presumably resulting in relatively stable concentrations of BCAAs in blood and tissues in humans. The main BCAA catabolic pathway is localized in the mitochondria of all tissues. The
-
br ABCA and cancer drug response Overall the
2024-09-03

ABCA2 and cancer drug response Overall, the expression of ABC transporters has been linked with multidrug resistance phenotypes through the efflux of drugs via ATP-dependent transport. For example, 13 distinct transporters (ABCA2, ABCB1, ABCB4, ABCB11, ABCC1–6 ABCC10, ABCC11 and ABCG2) have been
-
A number of studies suggest that adiponectin
2024-09-03

A number of studies suggest that adiponectin promotes osteoblast differentiation and bone formation by directly targeting GSK-3β and β-Catenin signaling [64], [65], favoring bone marrow mesenchymal stem cell (BMSC) differentiation toward the osteoblastic lineage [66], [67], decreasing sympathetic to
-
AMPK is an essential player in adiponectin
2024-09-03

AMPK is an essential player in adiponectin signaling pathway that regulates energy metabolism. The fact that suppression of AMPK activity by compound C largely diminished candesartan-mediated inhibition of NFκB via blocking AT1 also suggests that the AT1-mediated effect is at least partly resulted f
-
Because activation of HT A receptor is capable of
2024-09-03

Because activation of 5-HT2A receptor is capable of facilitating dopamine cell activity and dopamine release (Bortolozzi et al., 2003), and this action of dopamine is known to mediate rat maternal behavior, especially maternal motivation (Afonso et al., 2007, Febo et al., 2010, Li and Fleming, 2003,
-
In contrast to TPX members of the CPC Figure B
2024-09-03

In Cy3.5 maleimide to TPX2, members of the CPC (Figure 1B), such as survivin, borealin, and INCEN-P, which associate with Aurora B/C in animals, do not appear to have obvious homologs in plants. Recently, however, a putative INCEN-P homolog, termed WYRD, has been identified [34]. Sequence compariso
-
Acl converts cytosolic citrate CoA and
2024-09-03

Acl converts cytosolic citrate, CoA and ATP into acetyl-CoA, ADP+Pi and oxaloacetate (Fig. 1). This cytosolic enzyme is present in few Prokaryotes and in all Eukaryotes, but not in non-oleaginous yeasts [14]. Thus, this enzyme was presumed to be essential for FA synthesis [1], [13], [15]. In most mi
-
The tumor suppressor function of LOX
2024-09-03

The tumor-suppressor function of 15-LOX-2 in normal prostate epithelial cells may be explained by the induction of replicative senescence [14,15]. Thus, 15-LOX-2 is overexpressed in age-dependent prostatic hyperplasia, but cell senescence may hinder progression to malignant transformation. Notwithst
-
The LOX hydroxide metabolites are converted to secondary lip
2024-09-03

The 15-LOX hydroxide metabolites are converted to secondary lipid mediators such as lipoxin A4 from 15-HETE and protectin D1/resolvin D1 from 17-HDoHE [45] (Fig. S3). Importantly, all of these secondary lipid mediators have anti-inflammatory and pro-resolving properties [46], [47], [48]. Lipoxin A4
15940 records 89/1063 page Previous Next First page 上5页 8687888990 下5页 Last page